Skip to content
MARKETS / BALCAO / ALRTF
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

ALR Technologies SG Ltd. ALRTF

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$-22.1M
In brief

What this company does

ALR Singapore is a data management company that developed a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA-compliant Diabetes Solution product that can collect data from blood glucose meters (BGM) and continuous glucose monitors (CGM), a patent pending Predictive A1C algorithm to track treatment success between lab reports, and an FDA-cleared Insulin Dosing Adjustment program. From this technology portfolio, the company has developed the Diabetes Solution product for human health, and its GluCurve product for animal health. During 2011, the company received FDA clearance and achieved HIPAA compliance for an early version of its Diabetes Solution product. The company is actively seeking to commence revenue-generating activities for its Diabetes Solution product. In September 2023 the company announced the successful completion of its 24-week study led by Singapore General Hospital.

Written from the business description in ALR Technologies SG Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 30 April 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2023 · Revenue 0.0 · Net income -7.5
-4M-8M202020212022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2023 · Operating -29270.5% · Net 29270.5%
200000%400000%-50000%-100000%202020212022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks

Total assetsUSD 47,374.00
EquityUSD -39.9M
CashUSD 20,305.00
Gross debtUSD 3.1M
Net debtUSD 3.1M

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202520242023202220212020
Revenue $B··0.00.00.0·
Operating income $B−0.0−0.0−0.00.00.00.0
EBITDA $B······
Income tax $B······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.04−0.03−0.01−0.02··
Dividend / sh $······
Payout %······
ROE %······
Shares out B···0.550.54·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 21 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 74 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated innot stated in the filings
Fiscal year endsnot stated in the filings
Data on record since2020

Share this section

Download image